|
|
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismLILRB4 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Relapsed/Refractory Acute Myeloid Leukemia subjects.
HXYT-001细胞注射液治疗复发/难治B细胞非霍奇金淋巴瘤(B-NHL)的I期临床试验
[Translation] Phase I clinical trial of HXYT-001 cell injection for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL)
主要研究目的 评价 HXYT-001 细胞注射液治疗复发/难治 B-NHL 的安全性、耐受性,并确定 II 期推荐剂量(RP2D)。 次要研究目的 评价 HXYT-001 细胞注射液治疗复发/难治 B-NHL 的初步疗效; 评价 HXYT-001 的药代动力学(PK)特征; 评估 HXYT-001 的药效动力学(PD)特征; 评估 HXYT-001 的免疫原性。
[Translation] Primary study objectives To evaluate the safety and tolerability of HXYT-001 cell injection in the treatment of relapsed/refractory B-NHL and determine the Phase II recommended dose (RP2D). Secondary study objectives To evaluate the preliminary efficacy of HXYT-001 cell injection in the treatment of relapsed/refractory B-NHL; To evaluate the pharmacokinetic (PK) characteristics of HXYT-001; To evaluate the pharmacodynamic (PD) characteristics of HXYT-001; To evaluate the immunogenicity of HXYT-001.
100 Clinical Results associated with Beijing Qingyi Taike Pharmaceutical Technology Co., Ltd
0 Patents (Medical) associated with Beijing Qingyi Taike Pharmaceutical Technology Co., Ltd
100 Deals associated with Beijing Qingyi Taike Pharmaceutical Technology Co., Ltd
100 Translational Medicine associated with Beijing Qingyi Taike Pharmaceutical Technology Co., Ltd